Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples

Clinical Chemistry

Volumn 42, Issue 10, 1996, Pages 1634-1638

  Dittadi, Ruggero ^a   Barioli, Paola ^a   Gion, Massimo ^a   Mione, Riccardo ^a   Barichello, Mario ^a   Capitanio, Giovanni ^a   Cocco, Giovanni ^a   Cazzolato, Giuseppe ^a   De Biasi, Flora ^b   Praturlon, Silvio ^b   Antinozzi, Roberto ^c   Gianneo, Ernesto ^c  

^a Ospedale Civile   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c SANT ANNA HOSPITAL   (Italy)

Author keywords

bladder cancer; clinical diagnostics; method standardization

Indexed keywords

BIOCHEMICAL MARKER; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; PROTEIN DETERMINATION; STANDARDIZATION; URINALYSIS;

EID: 10244229693     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.10.1634     Document Type: Article

References (25)

1. Heney NM, Nocks BN, Daly JJ, Prout GR, Newall SB, Griffin PP, et al. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol 1982;54:152-7.
2. Mostofi FK, Davis DC Jr, Cesterhenn IA. Pathology of tumors of the urinary tract. In: Skinner DG, Lieskovsky G. eds. Genitourinary cancer. Philadelphia: WB Saunders, 1988:121-39.
3. Fair WR, Fuks ZY, Scher HI. Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer-principles and practice of oncology. Philadelphia: JB Lippincott Co., 1993:1052-72.
4. Wolf H, Hojgaard K. Urothelial displasia concomitant with bladder tumours as a determinant factor for future new occurrences. Lancet 1983;ii:134-9.
5. Umiker W. Accuracy of cytologic diagnosis of cancer of the urinary tract. Acta Cytol 1964;8:186-93.
6. Lewis RW, Jackson AC, Murphy WM, Leblanc GA, Meehan WL. Cytology in the diagnosis and follow-up of transitional cell carcinoma of the urothelium: a review with a case series. J Urol 1976;116:43-6.
7. Weiss MA. Urinary cytology of transitional cell neoplasm of the bladder. In: Young RH, ed. Pathology of the urinary bladder. New York: Churchill Livingstone, 1989:245-84.
8. Kumar S, Costello CB, Glashan RW, Björklund B. The clinical significance of tissue polypeptide antigen (TPA) in the urine of bladder cancer patients. Br J Urol 1981;53:578-81.
9. Tizzani A, Cassetta G, Cicigoi A, Piana P, Cerchier A, Pecchio F, et al. Tumor markers (CEA, TPA and CA19.9) in urine of bladder cancer patients. Int J Biol Markers 1987;2:121-4.
10. Halim A-B, El-Ahmady O, Hamza S, Aboul-Ela M, Oehr P. Simultaneous determination of urinary CEA, ferritin and TPA in Egyptian bladder cancer patients. Int J Biol Markers 1992;7:234-9.
11. Marzano D, Cianetti A, Mosseri D, Marino R, Lentini M. Validità di alcuni marcatori urinari (CEA, CA19.9, TPA) nella diagnosi e nel follow-up delle neoplasie superficiali della vescica. Acta Urol Ital 1992;1:35-7.
12. Casetta G, Piana P, Cavallini A, Vottero M, Tizzani A. Urinary levels of tumour associated antigens (CA19.9. TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities. Br J Urol 1993;72:60-4.
13. cyk and CYFRA21.1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 1994;9:70-5.
14. Senatore S, Zizzi L, Blasi C, Alfieri G, Saccani-Jotti G, Gabrielli M, et al. Tissue polypeptide antigen (TPA) in urinary bladder cancer cytology: a follow-up study. Oncology 1990;47:37-42.
15. Senatore S, Attolini A, Lucarelli S, Candita F, Trabucco M. Tissue polypeptide antigen in normal and neoplastic urinary bladder. Preliminary reports. Oncology 1987;44:118-23.
16. Bodenmüller H, Banauch D, Ofenloch B, Jaworek D. Dessauer A. Technical evaluation of a new automated tumor marker assay: the enzymun test CYFRA 21.1. In: Klapdor R, ed. Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Cancer of the breast - state and trends in diagnosis and therapy. München: Zuckschwerdt Verlag, 1992:137-8.
17. Weber K, Osborn M, Moll R, Wiklund B, Lüning B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumour marker. EMBO J 1984;3:2707-14.
18. Sundström BE, Nathrath WBJ, Stigbrand TI. Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J Histochem Cytochem 1989;37:1845-54.
19. Pujol J-L, Grenier J, Daures J-P, Michel F-B. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21.1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53: 61-6.
20. Stieber P, Hashholzner U, Bodenmuller H, et al. CYFRA 21.1, a new tumor marker in lung cancer. Cancer 1993;72:707-13.
21. Hasholzer U, Schambeck C, Fabricius PG, Steiber P, Hofmann K, Jansen HM, et al. Die klinische Relevanz des neuen Tumormarkers CYFRA 21.1 bei Blasenkarzinomen im Vergleich zu TPA und TPS. Lab Med 1993;17:324-2.
22. Steiber P, Dienemann H, Hashholzner U, Fabricius PG, Schambeck C, Weinzierl M, et al. A Comparison of CYFRA21.1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 1994;9:82-8.
23. Ciampi G, Pasquinelli F. Esame delle urine. In: Pasquinelli F, ed. Diagnostica e tecniche di laboratorio - chimica clinica. Firenze: Rosini Editrice, 1979:1493-546.
24. Gion M, Dittadi R, Munegato G, Mione R, Gurnari G, Zotti EF, et al. Tumor marker radioimmunoassays in gastric juice. Methodologic drawbacks due to pH variations. Gastroenterology 1988;94: 1271-5.
25. Ward AM. Standardization and quality control of tumour marker assays. Dis Markers 1991;9:127-32.